香雪製藥(300147.SZ)擬5784萬元轉讓“STP705項目”68.18%項目權益
格隆匯10月23日丨香雪製藥(300147.SZ)公佈,公司與蘇州聖諾生物醫藥技術有限公司(以下簡稱“蘇州聖諾”)及Sirnaomics.Inc.(以下簡稱“美國聖諾”)簽訂了《項目權益轉讓協議》及有關文件,根據協議內容,公司將持有的用於無疤痕皮膚傷口癒合的小核酸新藥項目(以下簡稱“STP705項目”)68.18%的項目權益以5784萬元的對價轉讓給蘇州聖諾。
本次合作項目屬於在研新藥,後續的研發需繼續投入且較大,可能存在藥品研發失敗、註冊不予批准或批准上市後產品盈利不達預期等風險。為將資源進一步向核心領域聚焦,不斷優化和完善研發產品管線,基於對該新藥目前的研發進度情況、潛在市場及長遠發展策略考慮,公司進行了本次交易。
截止目前,公司在該合作項目實際投入1,868.38萬元,公司和蘇州聖諾於2017年4月共同取得國家食品藥品監督管理總局藥物臨牀試驗批件,目前正在進行開展I期臨牀的準備工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.